Molecular and Pathophysiological Insights into the Pleiotropic Role of SGLT2i

Dear Colleagues,

Cardiovascular diseases are one of the main causes of morbidity and mortality worldwide, destined to increase their diffusion due to the aging of the world population. Over the last decades, there has been improvement in therapy, leaving a great impact on HF patients’ prognosis, especially in ones affected by HFrEF.

Among the latest additions to HF medical therapy are SGLT2 inhibitors (SGLT2i). Initially, these drugs were developed as anti-hyperglycemic drugs for type II diabetes therapy, but they were also found to be effective in the treatment of other clinical conditions such as heart failure and chronic kidney disease. Regarding their role in heart failure, clinical trials have shown SGLT2i to reduce CV events and mortality in patients with HF, improving cardiac metabolism, reducing cardiomyocytes injury and attenuating adverse cardiac remodeling. Based on the promising outcome of clinical trials, SGLT2i has been included in the four pillars of treatment for HFrEF, also becoming the first disease-modifying drug for HFpEF.

To better highlight the recent advances, this Special Issue will focus on the molecular and pathophysiological aspects of SGLT2i, considering their pleiotropic effects.

Specifically, original articles reporting completely new results or reviews of current literature on this aspect will be taken into account. The Special Issue aims to highlight both basic and translational research to allow for a more complete comprehension of the role of SGLT2i in the field of cardiovascular diseases.

Dr. Andrea D’Amato
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• sodium–glucose transport protein 2
• SGLT2i
• heart failure
• myocardial remodeling
• myocardial infarction
• myocarditis
• diabetic cardiomyopathy
• molecular signaling
• therapeutic benefits
• kidneys